PBRM1 表达在肾细胞癌中的预后和临床病理价值。

Prognostic and clinicopathological value of PBRM1 expression in renal cell carcinoma.

机构信息

Departments of Urology, Tianjin Institute of Urology, The Second Hospital of Tianjin Medical University, Tianjin 300211, China.

出版信息

Clin Chim Acta. 2018 Nov;486:9-17. doi: 10.1016/j.cca.2018.07.014. Epub 2018 Jul 11.

DOI:10.1016/j.cca.2018.07.014

PMID:30006290

Abstract

BACKGROUND

The prognostic value of PBRM1 expression in renal cell carcinoma (RCC) had been investigated in previous studies; however, the results remain inconclusive. We investigated the prognostic value and clinicopathological significance of PBRM1 protein expression in RCC.

METHODS

PubMed, Embase, Web of Science, and Cochrane database were searched for studies investigating the relationships between PBRM1 expression and outcomes in RCC. Hazard ratios (HRs) for survival outcomes and odds ratios (ORs) for clinical parameters were extracted from eligible studies. Heterogeneity was assessed using the I value. The fixed-effects model was used if there was no evidence of heterogeneity; otherwise, the random-effects model was used. Publication bias was evaluated using Begg's funnel plots and Egger's regression test.

RESULTS

A total of 2942 patients from 7 studies were included in the meta-analysis. The results showed that decreased expression of PBRM1 is associated with poor overall survival (OS) (HR = 2.11, 95% CI: 1.52-2.96), cancer-specific survival (CSS) (HR = 1.32, 95% CI: 1.10-1.58), and progression-free survival/ recurrence-free survival (PFS/RFS) (HR = 1.57, 95%CI: 1.34-1.85) in RCC. In addition, PBRM1 positive expression was significantly associated with earlier TNM stage (III/IV vs. I/II, OR = 0.53, 95% CI: 0.30-0.94), primary tumor stage (pT3/4 vs. pT1/2, OR = 0.32, 95% CI: 0.20-0.52), and Fuhrman grade (3/4 vs. 1/2, OR = 0.69, 95% CI: 0.46-1.02), but not related to Necrosis or Sex.

CONCLUSIONS

Decreased expression of PBRM1 is correlated with poor prognosis and advanced clinicopathological features in patients with RCC.

摘要

背景

先前的研究已经探讨了 PBRM1 表达在肾细胞癌（RCC）中的预后价值，但结果仍不确定。我们研究了 PBRM1 蛋白在 RCC 中的表达与预后的关系及其临床病理意义。

方法

在 PubMed、Embase、Web of Science 和 Cochrane 数据库中检索了研究 PBRM1 表达与 RCC 患者结局之间关系的文献。从合格的研究中提取生存结局的风险比（HRs）和临床参数的优势比（ORs）。使用 I ²值评估异质性。如果没有异质性证据，则使用固定效应模型；否则，使用随机效应模型。使用 Begg 漏斗图和 Egger 回归检验评估发表偏倚。

结果

共有 7 项研究的 2942 例患者纳入荟萃分析。结果表明，PBRM1 表达降低与总生存（OS）（HR=2.11，95%CI：1.52-2.96）、癌症特异性生存（CSS）（HR=1.32，95%CI：1.10-1.58）和无进展生存/无复发生存（PFS/RFS）（HR=1.57，95%CI：1.34-1.85）不良显著相关。此外，PBRM1 阳性表达与较晚的 TNM 分期（III/IV 期与 I/II 期，OR=0.53，95%CI：0.30-0.94）、原发肿瘤分期（pT3/4 期与 pT1/2 期，OR=0.32，95%CI：0.20-0.52）和 Fuhrman 分级（3/4 级与 1/2 级，OR=0.69，95%CI：0.46-1.02）显著相关，但与坏死或性别无关。